We advised the underwriters on the public offering

Davis Polk advised the representatives of the several underwriters, in connection with the $747.5 million public offering by Terns Pharmaceuticals, Inc. of 18,687,500 SEC-registered shares of common stock, which includes the exercise in full by the underwriters of their option to purchase additional shares. The common stock is listed on the Nasdaq Global Select Market under the symbol “TERN.”

Headquartered in Foster City, California, Terns Pharmaceuticals is a clinical-stage oncology company reimagining known biology to deliver high impact medicines. Its lead program TERN-701 is a highly selective, allosteric BCR-ABL inhibitor with a potentially best-in-disease profile that could meaningfully improve upon the efficacy, safety and convenience of existing treatments for chronic myeloid leukemia.

The Davis Polk corporate team included partner Yasin Keshvargar and associate Robert Van de Mark. Partner David R. Bauer and associate Gabrielle Mazero provided intellectual property advice. Counsel Christopher A. Baratta and associate Carter Ballentine Allison provided tax advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post